Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
Cyclacel Pharmaceuticals, Inc. (CYCC)
|
Add to portfolio |
|
|
|
| Price: |
$4.07
| | Metrics |
| OS: |
12.6
|
M
| |
-247
|
% ROE
|
| Market cap: |
$51.5
|
M
| |
-58796
|
% ROIC
|
|
Net cash:
|
$10.2
|
M
| |
$0.80
|
per share
|
|
EV:
|
$41.3
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($28.1)
|
M
| |
|
|
|
EBIT
|
($28.1)
|
M
| |
|
|
| EPS |
($1.97)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.8 | 1.7 |
| Revenue growth | | | | -100.0% | | -100.0% | -50.2% | -2.3% |
| Cost of goods sold | 27.7 | 22.9 | 10.6 | 9.7 | 9.7 | 0.0 | 15.0 | 18.1 |
| Gross profit | -27.7 | -22.9 | -10.6 | -9.7 | -9.5 | 0.0 | -14.2 | -16.4 |
| Gross margin | | | | | -6365.3% | | -1678.5% | -969.3% |
| Selling, general and administrative | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.5 | 0.0 | 0.0 |
| Research and development | | | | | | | | |
| EBIT | -27.2 | -22.9 | -10.6 | -9.4 | -9.3 | -9.4 | -13.8 | -16.6 |
| EBIT margin | | | | | -6204.7% | | -1641.8% | -978.7% |
| Pre-tax income | -25.9 | -22.7 | -9.7 | -9.1 | -8.6 | -8.5 | -13.8 | -16.5 |
| Income taxes | -4.7 | -3.8 | -1.2 | -1.3 | -1.3 | -1.0 | -2.0 | -2.1 |
| Tax rate | 18.2% | 16.9% | 12.8% | 14.2% | 15.5% | 11.7% | 14.4% | 13.0% |
| Net income | -21.2 | -18.9 | -8.4 | -7.8 | -7.3 | -7.5 | -11.8 | -14.3 |
| Net margin | | | | | -4858.7% | | -1398.7% | -846.6% |
| |
| Diluted EPS | ($1.88) | ($2.12) | ($2.32) | ($9.59) | ($0.60) | ($0.98) | ($3.44) | ($5.29) |
| Shares outstanding (diluted) | 11.3 | 8.9 | 3.6 | 0.8 | 12.1 | 7.6 | 3.4 | 2.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|